Abstract:The promise of genetic therapies has turned into reality in recent years, with new first-line treatments for fatal diseases now available to patients. The development and testing of genetic therapies for respiratory diseases such as cystic fibrosis (CF) has also progressed. The addition of gene editing to the genetic agent toolbox, and its early success in other organ systems, suggests we will see rapid expansion of gene correction options for CF in the future. Although substantial progress has been made in creating techniques and genetic agents that can be highly effective for CF correction in vitro, physiologically relevant functional in vivo changes have been largely prevented by poor delivery efficiency within the lungs. Somewhat hidden from view, however, is the absence of reliable, accurate, detailed, and noninvasive outcome measures that can detect subtle disease and treatment effects in the lungs of humans or animal models. The ability to measure the fundamental function of the lung-ventilation, the effective transport of air throughout the lung-has been constrained by the available measurement technologies. Without sensitive measurement methods, it is difficult to quantify the effectiveness of genetic therapies for CF. The mainstays of lung health assessment are spirometry, which cannot provide adequate disease localization and is not sensitive enough to detect small early changes in disease; and computed tomography, which provides structural rather than functional information. Magnetic resonance imaging using hyperpolarized gases is increasingly useful for lung ventilation assessment, and it removes the radiation risk that accompanies X-ray methods. A new lung imaging technique, X-ray velocimetry, can now offer highly detailed regional lung ventilation information well suited to the diagnosis, treatment, and monitoring needs of CF lung disease, particularly after the application of genetic therapies. In this review, we discuss the options now available for imaging-based lung function measurement in the generation and use of genetic and other therapies for treating CF lung disease.

Vapor-phase hydrothermal transformation of HTiOF3 intermediates into {001} faceted anatase single-crystalline nanosheets.

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

More Efficient Tagging Systems with Tag Seeding

New drugs, new challenges in cystic fibrosis care

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

Current landscape of cystic fibrosis gene therapy

The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon.

[Renal rickets].

Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis – where do we stand?

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies

Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis

The future of cystic fibrosis: A global perspective

Surface Properties of Poly[2-(perfluorooctyl)ethyl acrylate] Deposited from Liquid CO2 High-Pressure Free Meniscus Coating

Role of physical activity and airway clearance therapy in cystic fibrosis: moving forward in a rapidly changing landscape

Progress in Respiratory Gene Therapy

The evolving pharmacotherapy of pulmonary fibrosis

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

Will Airway Gene Therapy for Cystic Fibrosis Improve Lung Function? New Imaging Technologies Can Help Us Find Out

Genetic medicines for CF: Hype versus reality

Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis